AGIOS PHARMACEUTICALS, INC. Income Taxes Paid
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Income Taxes Paid of $74.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-07-30
- AGIOS PHARMACEUTICALS, INC. income taxes paid, net for the quarter ending 2026-06-30 was $70.00K, a 94.68% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. income taxes paid, net for the quarter ending 2026-03-31 was $4.00K, a 97.87% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. income taxes paid, net for the quarter ending 2025-12-31 was -$940.00K, a 102.15% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. income taxes paid, net for the quarter ending 2025-09-30 was $65.00K.
- AGIOS PHARMACEUTICALS, INC. income taxes paid, net for fiscal 2025 was $628.00K, a 98.54% decline from fiscal 2024.
- AGIOS PHARMACEUTICALS, INC. income taxes paid, net for fiscal 2024 was $43.15M, a 2650.16% increase from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. income taxes paid, net for fiscal 2023 was $1.57M.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $74.00K 10-Q · filed 2026-07-30 | -$866.00K derived: sum of 3 quarters · filed 2026-07-30 | -$801.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $4.00K 10-Q · filed 2026-04-29 | -$936.00K derived: sum of 2 quarters · filed 2026-04-29 | -$871.00K derived: sum of 3 quarters · filed 2026-04-29 | $444.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$940.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$875.00K derived: sum of 2 quarters · filed 2026-02-12 | $440.00K derived: sum of 3 quarters · filed 2026-07-30 | $628.00K 10-K · filed 2026-02-12 |
| 2025-09-30 | $65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.38M derived: sum of 2 quarters · filed 2026-07-30 | $1.57M 10-Q · filed 2025-10-30 | $45.35M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.50M 10-Q · filed 2026-07-30 | $45.29M derived: sum of 3 quarters · filed 2026-07-30 | $45.26M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $188.00K 10-Q · filed 2026-04-29 | $43.98M derived: sum of 2 quarters · filed 2026-04-29 | $43.94M derived: sum of 3 quarters · filed 2026-04-29 | $43.86M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $43.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $43.75M derived: sum of 2 quarters · filed 2026-02-12 | $43.67M derived: sum of 3 quarters · filed 2026-02-12 | $43.15M 10-K · filed 2026-02-12 |
| 2024-09-30 | -$34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$112.00K derived: sum of 2 quarters · filed 2025-10-30 | -$637.00K 10-Q · filed 2025-10-30 | -$654.00K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | -$78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$603.00K 10-Q · filed 2025-07-31 | -$620.00K derived: sum of 3 quarters · filed 2026-02-12 | $165.00K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | -$525.00K 10-Q · filed 2025-05-01 | -$542.00K derived: sum of 2 quarters · filed 2026-02-12 | $243.00K derived: sum of 3 quarters · filed 2026-02-12 | $1.04M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | -$17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $768.00K derived: sum of 2 quarters · filed 2026-02-12 | $1.57M derived: sum of 3 quarters · filed 2026-02-12 | $1.57M 10-K · filed 2026-02-12 |
| 2023-09-30 | $785.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $1.59M derived: sum of 2 quarters · filed 2024-10-31 | $1.59M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $801.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $801.00K 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | |||
| 2022-09-30 | $98.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $98.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.94M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.84M 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | $1.84M 10-Q · filed 2022-05-05 | |||
| 2021-09-30 | $2.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $8.92M derived: sum of 2 quarters · filed 2022-11-03 | $8.92M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $6.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $6.20M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |